A Phase 2 interventional study of BLI4900 and PEG Control in Colonoscopy, sponsored by Braintree Laboratories. Completed at 4 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-10-24.
Sponsored by Braintree Laboratories (part of Sebela Pharmaceuticals) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to evaluate the safety and efficacy of BLI4900 as a bowel preparation prior to colonoscopy in adult patients.
Braintree Laboratories is the lead sponsor of 49 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.
First submitted before Braintree Laboratories became part of Sebela Pharmaceuticals.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BLI4900 Bowel Preparation
Drug: BLI4900
Polyethylene glycol-based bowel preparation
Drug: PEG Control
BLI4900 Bowel Preparation
Polyethylene glycol-based bowel preparation
% of Subjects With Successful Bowel Preparation
% of subjects with successful bowel preparation rated by blinded colonoscopist on a 4 point scale (1=poor to 4 = excellent)
Time frame: Day of colonoscopy
| Milestone | BLI4900-3 | BLI4900-5 | BLI4900-6 | PEG-SD |
|---|---|---|---|---|
| Started | 21 | 40 | 41 | 19 |
| Completed | 21 | 40 | 40 | 19 |
| Not completed | 0 | 0 | 1 | 0 |
% of subjects with successful bowel preparation rated by blinded colonoscopist on a 4 point scale (1=poor to 4 = excellent)
| Participants | BLI4900-3 | BLI4900-5 | BLI4900-6 | PEG-SD |
|---|---|---|---|---|
| % of Subjects With Successful Bowel Preparation | 17 | 37 | 37 | 16 |
Collected over 2 days. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BLI4900-3 | 0/21 (0%) | 0/21 (0%) | 13/21 (61.9%) |
| BLI4900-5 | 0/40 (0%) | 0/40 (0%) | 31/40 (77.5%) |
| BLI4900-6 | 0/41 (0%) | 0/41 (0%) | 13/41 (31.7%) |
| PEG-SD | 0/19 (0%) | 1/19 (5.3%) | 14/19 (73.7%) |
| Event | BLI4900-3 | BLI4900-5 | BLI4900-6 | PEG-SD |
|---|---|---|---|---|
| diverticulitisGastrointestinal disorders | 0/21 | 0/40 | 0/41 | 1/19 |
| Event | BLI4900-3 | BLI4900-5 | BLI4900-6 | PEG-SD |
|---|---|---|---|---|
| abdominal distensionGastrointestinal disorders | 11/21 | 26/40 | 8/41 | 10/19 |
| nauseaGastrointestinal disorders | 7/21 | 19/40 | 5/41 | 7/19 |
| abdominal pain upperGastrointestinal disorders | 7/21 | 17/40 | 6/41 | 5/19 |
| vomitingGastrointestinal disorders | 3/21 | 2/40 | 3/41 | 1/19 |
| headacheNervous system disorders | 2/21 | 0/40 | 0/41 | 0/19 |
| hypernatremiaMetabolism and nutrition disorders | 0/21 | 0/40 | 0/41 | 1/19 |
| migraineNervous system disorders | 1/21 | 0/40 | 0/41 | 0/19 |
| orthostatic hypotensionVascular disorders | 1/21 | 1/40 | 0/41 | 0/19 |
| Age, Continuous(years) | BLI4900-3 | BLI4900-5 | BLI4900-6 | PEG-SD | Total |
|---|---|---|---|---|---|
| Mean | 54.8 ± 11.1 | 54.5 ± 11.5 | 58.7 ± 10.2 | 49.7 ± 15.7 | 55.2 ± 12.0 |
| Sex: Female, Male(Participants) | BLI4900-3 | BLI4900-5 | BLI4900-6 | PEG-SD | Total |
|---|---|---|---|---|---|
| Female | 10 | 20 | 24 | 12 | 66 |
| Male | 11 | 20 | 16 | 7 | 54 |
| Ethnicity (NIH/OMB)(Participants) | BLI4900-3 | BLI4900-5 | BLI4900-6 | PEG-SD | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 1 | 15 | 7 | 28 |
| Not Hispanic or Latino | 16 | 39 | 25 | 12 | 92 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | BLI4900-3 | BLI4900-5 | BLI4900-6 | PEG-SD | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 4 | 0 | 6 | 4 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 | 0 | 4 |
| Black or African American | 0 | 0 | 3 | 1 | 4 |
| White | 17 | 38 | 29 | 14 | 98 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | BLI4900-3 | BLI4900-5 | BLI4900-6 | PEG-SD | Total |
|---|---|---|---|---|---|
| United States | 21 | 40 | 40 | 19 | 120 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Nov 2019, 24 months.
Results were first posted in Oct 2023, 3 years 11 months after primary completion. A results delay was requested in Jan 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.